New Immunosuppressive Agents for the Treatment of Sjögren’s Syndrome

  • Steven Carsons


Despite the significant success in many immune-mediated disorders of disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and azathioprine, the demonstration of DMARD efficacy for the control of sicca and extraglandular symptoms of Sjögren’s syndrome (SS) has been elusive. This chapter will discuss potential applications of newer DMARDs for the management of primary SS (pSS) (Table 39.1).


Interstitial Lung Disease P2Y2 Receptor Salivary Flow Cutaneous Lupus Erythematosus Oral Dryness 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Kaltwasser JP, Behrens F. Leflunomide: long-term clinical experience and new uses. Expert Opin Pharmacother. 2005;6:787–801.PubMedCrossRefGoogle Scholar
  2. 2.
    Fox RI, Herrmann ML, Frangou CG, et al. How does leflunomide modulate the immune response in rheumatoid arthritis? BioDrugs. 1999;12:301–15.PubMedCrossRefGoogle Scholar
  3. 3.
    van Roon EN, Tim L, Jansen TL, et al. Leflunomide for the treatment of rheumatoid arthritis in clinical practice. Drug Saf. 2004;27:345–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Available from: (accessed october 11, 2011)
  5. 5.
    van Riel PL, Smolen JS, Emery P, et al. Leflunomide: a manageable safety profile. J Rheumatol Suppl. 2004;71:21–4.PubMedGoogle Scholar
  6. 6.
    Cannon GW, Strand V, Simon LS, et al. Interstitial lung disease in rheumatoid arthritis patients receiving leflunomide. Arthritis Rheum (Abstr). 2004;50:209.CrossRefGoogle Scholar
  7. 7.
    van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjögren’s syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Scagliusi P, D’Amore M, Scagliusi A, et al. Le nuove terapie nella syndromedi Sjögren: efficacia della Leflunomide. Reumatismo. 2004;56(3 Suppl 3):271 (Abstract P04).Google Scholar
  9. 9.
    Benucci M, LI Gobbi F, Pierfederici P. Modificazioni dei parametric della scintigrafia delle ghiandole salivary in corso di terapia con leflunomide in pazienti con syndrome di Sjögren. Reumatismo. 2004;56(3 Suppl 3):324 (Abstract P112).Google Scholar
  10. 10.
    Shiozawa S, Tanaka Y, Shiozawa K. Single-blinded controlled trial of low-dose oral IFN-alpha for the treatment of xerostomia in patients with Sjögen’s syndrome. J Interferon Cytokine Res. 1998;18:255–62.PubMedCrossRefGoogle Scholar
  11. 11.
    Ship JA, Fox PC, Michalek JE, et al. Treatment of primary Sjögren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res. 1999;19(8):943–51.PubMedCrossRefGoogle Scholar
  12. 12.
    Cummings MJ, Papas A, Kramer GM, Fox PC. Treatment of primary Sjögren’s syndrome with low-dose human interferon ala administered by the oromucosal route: combined phase III results. Arthritis Rheum. 2003;49(4):585–93.CrossRefGoogle Scholar
  13. 13.
    Yamada S, Nishimiya J, Nakajima T, Taketazu F. Interferon alfa treatment for Sjögren’s syndrome associated neuropathy. J Neurol Neurosurg Psychiatry. 2005;76:576–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Onishi S, Nagashima T, Kimura H, et al. Systemic lupus erythematosus and Sjögren’s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C. Lupus. 2010;19:753–5.PubMedCrossRefGoogle Scholar
  15. 15.
    Willeke P, Schlüter B, Becker H, et al. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial. Arthritis Res Ther. 2007;9:R115.PubMedCrossRefGoogle Scholar
  16. 16.
    Moutsopoulos HM, Fragoulis GE. Is mizoribine a new therapeutic agent for Sjögren’s syndrome? Nat Rev Rheumatol. 2008;4:350–1.Google Scholar
  17. 17.
    Nakayamada S, Saito K, Umehara H, et al. Efficacy and safety of Mizoribine for the treatment of Sjögren’s syndrome: a multicenter open-label clinical trial. Mod Rheumatol. 2007;17:464–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Nakayamada S, Fujimoto T, Nonomura A, et al. Usefulness of initial histological features for stratifying Sjögren’s syndrome responders to mizoribine therapy. Rheumatology. 2009;48:1279–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Arakawa T, Higuchi K, Fujiwara AY, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50 Suppl 1:S3–11.PubMedCrossRefGoogle Scholar
  20. 20.
    Sugai S, Takahashi H, Ohta S, et al. Efficacy and safety of rebamipide for the treatment of dry mouth symptoms in patients with Sjögren’s syndrome: a double-blind placebo-controlled multicenter trial. Mod Rheumatol. 2009;19:114–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Samarkos M, Moutsopoulos HM. Recent advances in the management of ocular complications of Sjögren’s syndrome. Curr Allergy Asthma Rep. 2005;5:327–32.PubMedCrossRefGoogle Scholar
  22. 22.
    Fischbarg J. Diquafosol tetrasodium. Inspire/Allegan/Santen. Curr Opin Investig Drugs. 2003;4:1377–83.PubMedGoogle Scholar
  23. 23.
    Spurgeon S, Yu M, Phillips JD, Epner EM. Cladribine: not just another purine analogue? Expert Opin Investig Drugs. 2009;18:1169–81.PubMedCrossRefGoogle Scholar
  24. 24.
    Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.PubMedCrossRefGoogle Scholar
  25. 25.
    Voulgarelis M, Petroutsos G, Moutsopoulos HM, Skopouli FN. 2-cholo-2′-deoxiadenosine in the treatment of Sjögren’s syndrome-associated B cell lymphoproliferation. Arthritis Rheum. 2002;46:2248–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Sekiguchi M, Iwasaki T, Kitano M, et al. Role of sphingosine 1-phosphate in the pathogenesis of Sjögren’s syndrome. J Immunol. 2008;180:1921–8.PubMedGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Steven Carsons
    • 1
    • 2
  1. 1.Division of Rheumatology, Allergy and ImmunologyWinthrop-University HospitalMineolaUSA
  2. 2.Department of MedicineStony Brook University School of MedicineStony BrookUSA

Personalised recommendations